HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Raises Price Target to $10

Benzinga Newsdesk www.benzinga.com Positive 70.5%

Neg 0% Neu 0% Pos 70.5%

HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and raises the price target from $7 to $10.